174 related articles for article (PubMed ID: 34996489)
41. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
42. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
43. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
[No Abstract] [Full Text] [Related]
44. Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib.
Hu F; Guo L; Yu J; Dai D; Xiong Y; He Y; Zhou W
Pathol Oncol Res; 2021; 27():1610008. PubMed ID: 34955687
[No Abstract] [Full Text] [Related]
45. Primary pulmonary NUT midline carcinoma: An elusive and a rare diagnostic entity.
Pasricha S; Jajodia A; Sharma A; Bansal D; Batra U; Gupta G; Durga G; Kamboj M; Nathany S; Mehta A
J Cancer Res Ther; 2023; 19(3):816-818. PubMed ID: 37470617
[TBL] [Abstract][Full Text] [Related]
46. Anlotinib: First Global Approval.
Syed YY
Drugs; 2018 Jul; 78(10):1057-1062. PubMed ID: 29943374
[TBL] [Abstract][Full Text] [Related]
47. Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
Bishop JA; French CA; Ali SZ
Cancer Cytopathol; 2016 Dec; 124(12):901-908. PubMed ID: 27400194
[TBL] [Abstract][Full Text] [Related]
48. Midline carcinoma expressing NUT in malignant effusion cytology.
Shenoy KD; Stanzione N; Caron JE; Fishbein GA; Abtin F; Lluri G; Hirschowitz SL
Diagn Cytopathol; 2019 Jun; 47(6):594-598. PubMed ID: 30734527
[TBL] [Abstract][Full Text] [Related]
49. Case Report and Literature Review: Primary Pulmonary NUT-Midline Carcinoma.
Zhang Y; Han K; Dong X; Hou Q; Li T; Li L; Zhou G; Liu X; Zhao G; Li W
Front Oncol; 2021; 11():700781. PubMed ID: 34527578
[TBL] [Abstract][Full Text] [Related]
50. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
51. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
[No Abstract] [Full Text] [Related]
52. HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report.
Esteves G; Ferreira J; Afonso R; Martins C; Zagalo C; Félix A
Head Neck Pathol; 2020 Dec; 14(4):1117-1122. PubMed ID: 31989434
[TBL] [Abstract][Full Text] [Related]
53. Nuclear protein in testis midline carcinoma with unusual elevation of α-fetoprotein and synaptophysin positivity: a case report and review of the literature.
Raza A; Cao H; Conrad R; Cobb C; Castelino-Prabhu S; Mirshahidi S; Shiraz P; Mirshahidi HR
Expert Rev Anticancer Ther; 2015; 15(10):1199-213. PubMed ID: 26402248
[TBL] [Abstract][Full Text] [Related]
54. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
[TBL] [Abstract][Full Text] [Related]
55. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
56. NUT midline lung cancer: a rare case report with literature review.
Gupta R; Mumaw D; Antonios B; Anusim N; Dhulipalla SP; Stender M; Huben M; Jaiyesimi I
AME Case Rep; 2022; 6():2. PubMed ID: 35128310
[TBL] [Abstract][Full Text] [Related]
57. Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases.
Giridhar P; Mallick S; Kashyap L; Rath GK
Eur Arch Otorhinolaryngol; 2018 Mar; 275(3):815-821. PubMed ID: 29356890
[TBL] [Abstract][Full Text] [Related]
58. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
59. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
[No Abstract] [Full Text] [Related]
60. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
